arXiv · 1210.3154
Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites
Abstract
HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.
Explore related subjects
Keep this discovery
Subhomoi Borkotoky. 2012-10-11. Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites. https://doi.org/10.5121/ijbb.2012.2303
Cite the original work for its findings. Save a collection to share your selection of sources.